Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study. Issue 1 (January 2021)
- Record Type:
- Journal Article
- Title:
- Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study. Issue 1 (January 2021)
- Main Title:
- Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study
- Authors:
- Adams, David
Polydefkis, Michael
González-Duarte, Alejandra
Wixner, Jonas
Kristen, Arnt V
Schmidt, Hartmut H
Berk, John L
Losada López, Inés Asunción
Dispenzieri, Angela
Quan, Dianna
Conceição, Isabel M
Slama, Michel S
Gillmore, Julian D
Kyriakides, Theodoros
Ajroud-Driss, Senda
Waddington-Cruz, Márcia
Mezei, Michelle M
Planté-Bordeneuve, Violaine
Attarian, Shahram
Mauricio, Elizabeth
Brannagan, Thomas H
Ueda, Mitsuharu
Aldinc, Emre
Wang, Jing Jing
White, Matthew T
Vest, John
Berber, Erhan
Sweetser, Marianne T
Coelho, Teresa
Vita, Giuseppe
Rizzo, Vincenzo
Russo, Massimo
Mazzeo, Anna
Gentile, Luca
Berk, John L
Brueckner, Caitlin
Lazzari, Victoria
Wiesman, Janice
DeLong, Douglas
Victory, Jennifer
Dalton, James
May, John
Gilmore, Catherine
Attarian, Shahram
Diallo, Saran
Delmont, Emilien
Pouget, Jean
Verschueren, Annie
Grapperon, Aude-Marie
Campana-Salort, Emmanuelle
Conceição, Isabel M
Lopes, Ana
Lamas, Filipa
Neves, Carlos
Castro, Jose
Pereira, Pedro
Castro, Isabel
Franco, Ana
Santos, Miguel Oliveira
de Azevedo Coutinho, Conceição
Falcao de Campos, Catarina
Coelho, Teresa
Hipólito Reis, Antonio
Correia, Nuno
Perez, Javier M
Martins da Silva, Ana
Alves, Cristina
Cardoso, Marcio
Valdrez, Katia
Monte, Julia R
Pessoa, Bernardete
Guimaraes, Nadia
Freitas, Monica
Ramalho, Joana
Ferreira, Natalia
Kuzume, Daisuke
Tard, Celine
Waucquier, Nawal
Rougeaux, Isabelle
Brice, Sylvie
Kasprzyk, Emmanuelle
Elrezzi, Elise
Meguig, Sayah
Hachulla, Eric
Gauvain, Clement
Migaud-Chervy, Maria-Claire
Deplanque, Dominique
Jozefowicz, Elsa
Lebellec, Loic
Adams, David
Balaya-Gouraya, Line
Jehan Lacour, Nathalie
Bournane, Halima
Martin, Nathalie
Elabed, Mongia
Sacko, Niamey
Boubrit, Yasmine
Gaouar, Amina
Rakotondratafika, Fetra
Théaudin-Saliou, Marie
Cauquil-Michon, Cécile
Labeyrie, Celine
Not, Adeline
Al-Salameh, Abdallah
Lecoq, Anne-Lise
Stephant, Maeva
Echaniz-Laguna, Andoni
Becquemont, Laurent
Beaudonnet, Guillemette
Algalarrondo, Vincent
Eliahou, Ludivine
Slama, Michel S
Signate, Aissatou
Berthelot, Emeline
Inamo, Jocelyn
Planté-Bordeneuve, Violaine
Vervoitte, Laetitia
Focseneanu, Cecile
Gendre, Thierry
Arrouasse, Raphaele
Ayache, Samar S.
Ernande, Laura
Le Corvoisier, Philippe
Salhi, Hayet
Choumert, Ariane
Ehinger, Vincent
Ruiz, Julie
Charlin, Cyril
Megelin, Thomas
Brannagan III, Thomas H
Fayerman, Raisy
Kim, Arreum
Paras, Allan
Gonzalez, Leidy J
Tsang, Steven
Wajnsztajn, Fernanda
Shije, Jeffrey
Ulane, Christina
Kleyman, Inna
Weimer, Louis
Cioroiu, Comana
Lambrianides, Sakis
Abu-Manneh, Rana
Zamba-Papanicolaou, Eleni
Agathangelou, Petros
Leonidou, Eleni
Kyriakides, Theodoros
Tada, Satoshi
Fujita, Akemi
Nagai, Masahiro
Ando, Rina
Hosokawa, Yuko
Yamanishi, Yuki
Overcash, J. Scott
Giardino, Elena
Boyer, Leslie
Dang, Lien
Le, An
Nguyen, Tyler
Giang, Lien
Sellers, Peter
Tran, Leyla
Truong, Nghi
Vinas, Maita
Hrkman, Nicole
Miller, Sarah
Nguyen, David
Smith, Ashley
Pu, Helen
Li, Steve
Vuong, Thao
Dioso, Holly
Green, Sinikka
Lee, Kia
Chu, Hanh
Waters, Michael
Coskun, Derya J
Zepeda, Karla A
O'Riordan, William
Obici, Laura
Cortese, Andrea
Lozza, Alessandro
Merlini, Giampaolo
Rosti, Vittorio
Sabatelli, Mario
Bisogni, Giulia
Bernardo, Daniela
Luigetti, Marco
Di Paolantonio, Andrea
Guglielmino, Valeria
Bisogni, Giulia
Romano, Angela
Nienhuis, Hans
Bulthuis-Kuiper, Janita
Kristen, Arnt V
Gerk, Olga
Ulbricht, Hannah
Taylor, Lenka
Meyle, Eva
Kleinschmidt, Natalia
Meyrath, David
Noe-Schwenn, Simone
Meng, Ulrike
Bauer, Ralf
aus dem Siepen, Fabian
Hein, Selina
Takahashi, Tetsuya
Oshita, Tomohiko
Koujin, Yoko
Neshige, Shuichiro
Nezu, Tomohisa
Segawa, Akiko
Ueno, Hiroki
Morino, Hiroyuki
Campistol, Josep M
Rodas Marin, Lida Maria
Blasco Pelicano, Josep Miquel
Dávila, Lucía Galán
Palacios, Marta
Pytel Cordoba, Vanesa
Guerrero Sola, Antonio
Horga, Alejandro
García Feijoo, Julián
Perez de Isla, Leopoldo
Marques Júnior, Wilson
Moscardini, Mariana
Litcanov, Debora Cristina
Viera Lima, Ana Flavia
Rodrigues, Leonardo
Marques Coutinho, Barbara
Moreira, Carolina Lavigne
Daccach Marques, Vanessa
Munoz Beamud, Francisco
Gragera Martínez, Álvaro
Borrachero, Cristina
Losada López, Inés Asunción
Cisneros Barroso, Eugenia
Rodríguez Rodríguez, Adrián
Sanz, Monica
Rigo Oliver, Elena
González Moreno, Juan
Gamez Martinez, Jose M
Descals, Cristina
Uson, Mercedes
Jose Vega, Francisco
Figuerola, Antoni
Montala, Carles
Waddington-Cruz, Márcia
Dias da Silva, Moises
Gervais de Santa Rosa, Renata
Pinto, Luiz Felipe
Pinto, Marcus Vinicius
Cardoso Berensztejn, Amanda
Barroso, Fabio
Lautre, Andrea
Orellana, Lucas G
González-Duarte Briseño, Maria Alejandra
Cárdenas-Soto, Karla
Jiménez López, Brenda Poled
Pérez-Castañeda, Sandra Lorena
Cantú Brito, Carlos Gerardo
Rivera de la Parra, David
Hernandez Reyes, Jose Pablo
del Mar Saniger Alba, Maria
Criollo Mora, Elia
Parman, Yesim
Rezzan, Kus Jülide
Sahin, Erdi
Serbest, Nail G
Durmus, Hacer
Cakar, Arman
Tugal Tutkun, Nuriye Ilknur
Karamursel, Sacit
Elitok, Ali
Sirin Inan, Nermin G
Altinkurt, Emre
Polydefkis, Michael
Ye, Jing
Allen, Adriane C
Chaudhry, Vinay
Jarrett, Raquel
Bressler, Neil
Burks, Kathleen L
Liu, Qingfeng
Khoshnoodi, Mohammad
Judge, Daniel P
Vista, Geno
Shah, Syed Mahmood
Hamaguchi, Hirotoshi
Oda, Junko
Fukase, Emi
Taniguchi, Ikuko
Oda, Tetsuya
Endo, Hironobu
Shimomura, Masahiro
Katanazaka, Kimitaka
Koto, Shusuke
Nakano, Takahiro
Scheid, Christof
Zueiter, Andreas
Pester, Lars
Walter, Doreen
Özdemir, Betül
Frenzel, Lukas F
Holtick, Udo
Oh, Jeeyoung
Kim, Hee Jin
Shin, Hyun Jin
Choi, Kyomin
Yamashita, Taro
Ueda, Mitsuharu
Masuda, Teruaki
Misumi, Yohei
Ueda, Akihiko
Nakahara, Keiichi
Yorita, Akiko
Tsuruhisa, Seiko
Taniwaki, Takayuki
Harada, Masaya
Moritaka, Taiga
Sakurada, Naonori
Mauricio, Elizabeth A
Baskin, Amber
Dimberg, Elliot
Dispenzieri, Angela
Fonder, Amie
Hobbs, Miriam
Russell, Stephen J
Dyck, Peter
Gonsalves, Wilson
Leung, Nelson
Witzig, Thomas E
Zeldenrust, Steven R
Hwa, Lisa
Kapoor, Prashant
Kumar, Shaji K
Lin, Yi
Lust, John A
Rajkumar, Vincent S
Dingli, David
Gertz, Morie A
Go, Ronald
Hayman, Suzanne R
Dalia, Samir
Carrillo, Esmeralda
Gorevic, Peter
Mason, Garnette
Chao, Chi-Chao
Lee, Ming-Jen
Su, Jen-Jen
Hsieh, Sung-Tsang
Tsai, Li-Kai
Yeh, Shin-Joe
Yang, Chih-Chao
Ajroud-Driss, Senda Ajroud-Driss
Casey, Patricia
Joslin, Benjamin C
Freimer, Miriam
Sankey, Alison
Kenepp, Amanda
Heintzman, Sarah
LoRusso, Samantha
Hokezu, Youichi
Kim, Byoung-Joon
Kim, JuHyeon
Lee, Ga Yeon
Cho, Eun Bin
Jeon, Eun-Seok
Min, Ju-Hong
Seok, Jin Myoung
Lee, Hye Lim
Park, Jae Hong
Sekijima, Yoshiki
Miyazawa, Chinatsu
Kato, Nagaaki
Kishida, Dai
Hineno, Akiyo
Kodaira, Minori
Yoshinaga, Tsuneaki
Miyahara, Teruyoshi
Imai, Akira
Matsumoto, Kazuhiko
Lin, Kon-Ping
Lee, Yi-Chung
Wixner, Jonas
Falk, Malin
Pilebro, Bjorn
Suhr, Ole
Lindqvist, Per
Soderberg, Karin
Pedrosa-Domellöf, Fatima
Anan, Intissar
Nordh, Erik
Tournev, Ivaylo
Zhelyazkova-Glaveeva, Sashka
Cherneva, Zheyna
Sarafov, Staiko
Chamova, Teodora
Cherninkova-Gopina, Sylvia
Schmidt, Hartmut H
Friebel, Frauke
Zibert, Andree
Mihailovic, Natasa
Schubert, Friederike
Vorona, Elena
Lahme, Larissa
Huesing-Kabar, Anna
Schilling, Matthias
Kabar, Iyad
Gillmore, Julian D
Martinez-Naharro, Ana
Chacko, Liza
Cohen, Oliver
Law, Steven
Rezk, Tamer
Lachmann, Helen J
Quan, Dianna
Blume, Brianna
Dixon, Stacy
Low, Soon Chai
Chan, Soo Looi
Lim, He Eng Li
Goh, Khean Jin
Mezei, Michelle M
Kraus, Deborah
Jack, Kristin
Lopate, Glenn
Zwijack, Brittany
Florence, Julaine
Sommerville, R. Brian
Stewart, Graeme
Ryder, Julie
Mekhael, Linda
Taylor, Mark
Suan, Daniel
Wells, Karen
Stone, Paula
Wells, Karen
Itoya, Amenze
Owusu-Sekyere, Mercy
Thai, Desmond
Chahine, Ilonah
Pedrosa, Salve
Do, Thi Hoa (Therese)
… (more) - Abstract:
- Summary: Background: Hereditary transthyretin-mediated amyloidosis is a rare, inherited, progressive disease caused by mutations in the transthyretin ( TTR ) gene. We assessed the safety and efficacy of long-term treatment with patisiran, an RNA interference therapeutic that inhibits TTR production, in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy. Methods: This multicentre, open-label extension (OLE) trial enrolled patients at 43 hospitals or clinical centres in 19 countries as of Sept 24, 2018. Patients were eligible if they had completed the phase 3 APOLLO or phase 2 OLE parent studies and tolerated the study drug. Eligible patients from APOLLO (patisiran and placebo groups) and the phase 2 OLE (patisiran group) studies enrolled in this global OLE trial and received patisiran 0·3 mg/kg by intravenous infusion every 3 weeks with plans to continue to do so for up to 5 years. Efficacy assessments included measures of polyneuropathy (modified Neuropathy Impairment Score +7 [mNIS+7]), quality of life, autonomic symptoms, nutritional status, disability, ambulation status, motor function, and cardiac stress, with analysis by study groups (APOLLO-placebo, APOLLO-patisiran, phase 2 OLE patisiran) based on allocation in the parent trial. The global OLE is ongoing with no new enrolment, and current findings are based on the interim analysis of the patients who had completed 12-month efficacy assessments as of the data cutoff. Safety analysesSummary: Background: Hereditary transthyretin-mediated amyloidosis is a rare, inherited, progressive disease caused by mutations in the transthyretin ( TTR ) gene. We assessed the safety and efficacy of long-term treatment with patisiran, an RNA interference therapeutic that inhibits TTR production, in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy. Methods: This multicentre, open-label extension (OLE) trial enrolled patients at 43 hospitals or clinical centres in 19 countries as of Sept 24, 2018. Patients were eligible if they had completed the phase 3 APOLLO or phase 2 OLE parent studies and tolerated the study drug. Eligible patients from APOLLO (patisiran and placebo groups) and the phase 2 OLE (patisiran group) studies enrolled in this global OLE trial and received patisiran 0·3 mg/kg by intravenous infusion every 3 weeks with plans to continue to do so for up to 5 years. Efficacy assessments included measures of polyneuropathy (modified Neuropathy Impairment Score +7 [mNIS+7]), quality of life, autonomic symptoms, nutritional status, disability, ambulation status, motor function, and cardiac stress, with analysis by study groups (APOLLO-placebo, APOLLO-patisiran, phase 2 OLE patisiran) based on allocation in the parent trial. The global OLE is ongoing with no new enrolment, and current findings are based on the interim analysis of the patients who had completed 12-month efficacy assessments as of the data cutoff. Safety analyses included all patients who received one or more dose of patisiran up to the data cutoff. This study is registered with ClinicalTrials.gov, NCT02510261 . Findings: Between July 13, 2015, and Aug 21, 2017, of 212 eligible patients, 211 were enrolled: 137 patients from the APOLLO-patisiran group, 49 from the APOLLO-placebo group, and 25 from the phase 2 OLE patisiran group. At the data cutoff on Sept 24, 2018, 126 (92%) of 137 patients from the APOLLO-patisiran group, 38 (78%) of 49 from the APOLLO-placebo group, and 25 (100%) of 25 from the phase 2 OLE patisiran group had completed 12-month assessments. At 12 months, improvements in mNIS+7 with patisiran were sustained from parent study baseline with treatment in the global OLE (APOLLO-patisiran mean change –4·0, 95 % CI –7·7 to −0·3; phase 2 OLE patisiran –4·7, –11·9 to 2·4). Mean mNIS+7 score improved from global OLE enrolment in the APOLLO-placebo group (mean change from global OLE enrolment −1·4, 95% CI –6·2 to 3·5). Overall, 204 (97%) of 211 patients reported adverse events, 82 (39%) reported serious adverse events, and there were 23 (11%) deaths. Serious adverse events were more frequent in the APOLLO-placebo group (28 [57%] of 49) than in the APOLLO-patisiran (48 [35%] of 137) or phase 2 OLE patisiran (six [24%] of 25) groups. The most common treatment-related adverse event was mild or moderate infusion-related reactions. The frequency of deaths in the global OLE was higher in the APOLLO-placebo group (13 [27%] of 49), who had a higher disease burden than the APOLLO-patisiran (ten [7%] of 137) and phase 2 OLE patisiran (0 of 25) groups. Interpretation: In this interim 12-month analysis of the ongoing global OLE study, patisiran appeared to maintain efficacy with an acceptable safety profile in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy. Continued long-term follow-up will be important for the overall assessment of safety and efficacy with patisiran. Funding: Alnylam Pharmaceuticals. … (more)
- Is Part Of:
- Lancet neurology. Volume 20:Issue 1(2021)
- Journal:
- Lancet neurology
- Issue:
- Volume 20:Issue 1(2021)
- Issue Display:
- Volume 20, Issue 1 (2021)
- Year:
- 2021
- Volume:
- 20
- Issue:
- 1
- Issue Sort Value:
- 2021-0020-0001-0000
- Page Start:
- 49
- Page End:
- 59
- Publication Date:
- 2021-01
- Subjects:
- Neurology -- Periodicals
Neurology -- Periodicals
Nervous System Diseases -- Periodicals
Neurologie -- Périodiques
Neurology
Electronic journals
Periodicals
616.805 - Journal URLs:
- http://www.thelancet.com/journals/laneur ↗
http://www.sciencedirect.com/science/journal/14744422 ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1016/S1474-4422(20)30368-9 ↗
- Languages:
- English
- ISSNs:
- 1474-4422
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 5146.084000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 15373.xml